Gao Qing-Lei, Ye Fei, Li Jing, Xing Hui, Lu Yun-Ping, Ma Ding
Department of Obstetrics &Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.
Ai Zheng. 2003 Jun;22(6):640-4.
BACKGROUND & OBJECTIVE: A new candidate tumor suppressor gene, called phosphatase and tension homology deleted on chromosome ten (PTEN), was the first gene that was found to be phospholipase tumor suppressor gene. Loss of PTEN function by mutation or other mechanisms is closely related to tumorigenesis and progression of multiple carcinomas. This study was designed to investigate the expression of PTEN in carcinogenesis and development of endometrium carcinoma.
The expression of PTEN were detected by reverse transcription polymerase chain reaction (RT-PCR) for 24 cases with endometrial carcinoma, 10 cases with endometrial atypical hyperplasia, 10 cases with endometrial hyperplasia,and 10 cases with normal endometrium and by SP immunohistochemical methods for 73 cases with endometrial carcinoma, 25 cases with endometrial atypical hyperplasia, 71 cases with endometrial hyperplasia,and 31 cases with normal endometrium. The results were compared with clinical parameters (histological classification, differentiation, depth of myometrium invasion, and clinical stage).
PTEN expression levels of both RNA and protein in patients with endometrial carcinoma and endometrial atypical hyperplasia were significantly lower than those in patients with endometrial hyperplasia and normal endometrium. mRNA relative values were 0.35+/-0.13, 0.46+/-0.11, 2.32+/-0.32, and 2.45+/-0.51, respectively. Loss of PTEN expression rates were 66.67% (38/57), 76.00% (19/25), 5.63% (4/71), and 0 (0/31), respectively. Loss of PTEN expression in patients with endometrial carcinoma was significantly related to histological classification (P< 0.0001) and differentiation (P=0.0349). It was not related to depth of myometrium invasion and clinical stage(P >0.05).
Loss of PTEN expression is an early event in endometrial tumorigenesis. Detection of PTEN protein may be a diagnostic biomarker for the earliest endometrial precancers and adenocarcinoma.
一种新的候选肿瘤抑制基因，称为10号染色体缺失的磷酸酶和张力同源基因（PTEN），是首个被发现的磷脂酶肿瘤抑制基因。PTEN功能因突变或其他机制丧失与多种癌症的发生和进展密切相关。本研究旨在探讨PTEN在子宫内膜癌发生发展中的表达情况。
采用逆转录聚合酶链反应（RT-PCR）检测24例子宫内膜癌、10例子宫内膜非典型增生、10例子宫内膜增生及10例正常子宫内膜组织中PTEN的表达；采用SP免疫组化法检测73例子宫内膜癌、25例子宫内膜非典型增生、71例子宫内膜增生及31例正常子宫内膜组织中PTEN的表达。将结果与临床参数（组织学分类、分化程度、肌层浸润深度及临床分期）进行比较。
子宫内膜癌及子宫内膜非典型增生患者中PTEN的RNA和蛋白表达水平均显著低于子宫内膜增生及正常子宫内膜患者。mRNA相对值分别为0.35±0.13、0.46±0.11、2.32±0.32及2.45±0.51。PTEN表达缺失率分别为66.67%（38/57）、76.00%（19/25）、5.63%（4/71）及0（0/31）。子宫内膜癌患者PTEN表达缺失与组织学分类（P<0.0001）及分化程度（P=0.0349）显著相关，与肌层浸润深度及临床分期无关（P>0.05）。
PTEN表达缺失是子宫内膜肿瘤发生的早期事件。检测PTEN蛋白可能是早期子宫内膜癌前病变及腺癌的诊断生物标志物。
